

Appraisal of patient-reported outcome measures in ana recommendations for use in phase II and III clinical tria

Quality of Life Research

28, 399-410

DOI: [10.1007/s11136-018-2025-y](https://doi.org/10.1007/s11136-018-2025-y)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment: Disease-specific assessments. <i>European Journal of Haematology</i> , 2020, 104, 427-434.	2.2	9
2	The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment. <i>Patient</i> , 2021, 14, 485-503.	2.7	31
3	Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. <i>Blood Advances</i> , 2022, 6, 1844-1853.	5.2	12
4	Development of Patient-Reported Outcome Measures (Symptoms and Impacts) in Adults with Pyruvate Kinase Deficiency. <i>Blood</i> , 2019, 134, 3447-3447.	1.4	0
5	Pyruvate kinase deficiency: epidemiology, molecular analyses and modern diagnostic approaches (literature review). <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2020, 7, 86-93.	0.3	0
6	Experienced fatigue in people with rare disorders: a scoping review on characteristics of existing research. <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 14.	2.7	7
7	Mitapivat versus Placebo for Pyruvate Kinase Deficiency. <i>New England Journal of Medicine</i> , 2022, 386, 1432-1442.	27.0	42
8	Pyruvate Kinase Deficiency: Current Challenges and Future Prospects. <i>Journal of Blood Medicine</i> , 0, Volume 13, 461-471.	1.7	10
9	Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial. <i>Journal of Patient-Reported Outcomes</i> , 2023, 7, .	1.9	0